The use of thalidomide in androgen-independent prostate cancer{star, open}

Urologic Oncology: Seminars and Original Investigations

Volumn 24, Issue 3, 2006, Pages 246-249

  Cox, Michael C ^a   Dahut, William L ^a   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Hormones; Oncology; Prostate cancer; Thalidomide

Indexed keywords

ANDROGEN; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; DOCETAXEL; ENOXAPARIN; ESTRAMUSTINE PHOSPHATE; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ALLELE; ANDROGEN INDEPENDENT PROSTATE CANCER; ANGIOGENESIS; CANCER DIAGNOSIS; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONGENITAL MALFORMATION; CONSTIPATION; CORRELATION ANALYSIS; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FATIGUE; HUMAN; LIMB MALFORMATION; MOOD CHANGE; MOOD DISORDER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ANGIOGENESIS INHIBITORS; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; THALIDOMIDE;

EID: 33646201477     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2005.11.020     Document Type: Review

References (27)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. Rini B., and Small E.J. An update on prostate cancer. Curr Opin Oncol 13 (2001) 204-211
3. Crawford E.D., Eisenberger M.A., McLeod D.G., et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321 (1989) 419-424
4. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
5. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
6. Folkman J. Tumour angiogenesis. Therapeutic implications. N Engl J Med 285 (1971) 1182-1186
7. Bostwick D.G., and Iczkowski K.A. Microvessel density in prostate cancer. Prognostic and therapeutic utility. Semin Urol Oncol 16 (1998) 118-123
8. Jones A., and Fujiyama C. Angiogenesis in urological malignancy. Prognostic indicator and therapeutic target. BJU Int 83 (1999) 535-555
9. Lissbrant I.F., Lissbrant E., Damber J.E., et al. Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer. Scand J Urol Nephrol 35 (2001) 437-452
10. Siegal J.A., Yu E., and Brawer M.K. Topography of neovascularity in human prostate carcinoma. Cancer 75 (1995) 2545-2551
11. Wakui S., Furusato M., Itoh T., et al. Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis. A morphometric study. J Pathol 168 (1992) 257-262
12. Weidner N., Carroll P.R., Flax J., et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143 (1993) 401-409
13. D'Amato R.J., Loughnan M.S., Flynn E., et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91 (1994) 4082-4085
14. Lenz W. A short history of thalidomide embryopathy. Teratology 38 (1988) 203-215
15. Teo S.K., Resztak K.E., Scheffler M.A., et al. Thalidomide in the treatment of leprosy. Microbes Infect 4 (2002) 1193-1202
16. Bauer K.S., Dixon S.C., and Figg W.D. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 55 (1998) 1827-1834
17. Ando Y., Fuse E., and Figg W.D. Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res 8 (2002) 1964-1973
18. Moreira A.L., Sampaio E.P., Zmuidzinas A., et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177 (1993) 1675-1680
19. Sampaio E.P., Sarno E.N., Galilly R., et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173 (1991) 699-703
20. Franks M.E., Macpherson G.R., and Figg W.D. Thalidomide. Lancet 363 (2004) 1802-1811
21. Figg W.D., Dahut W., Duray P., et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 7 (2001) 1888-1893
22. Drake M.J., Robson W., Mehta P., et al. An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer 88 (2003) 822-827
23. Dahut W.L., Gulley J.L., Arlen P.M., et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 22 (2004) 2532-2539
24. Ando Y., Price D.K., Dahut W.L., et al. Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide. Cancer Biol Ther 1 (2002) 669-673
25. Horne III M.K., Figg W.D., Arlen P., et al. Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer. Pharmacotherapy 23 (2003) 315-318
26. Picus J. Docetaxel/bevacizumab (Avastin) in prostate cancer. Cancer invest, Chemotherapy Foundation Symposium XXI (2004) New York (NY)
27. Bok R.A., Halabi S., Fei D.T., et al. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients. A cancer and leukemia group B study. Cancer Res 61 (2001) 2533-2536